Eupraxia Pharamceuticals Shares Are Trading Higher After the Company Announced It Published Its Phase 2 Data From Its SPRINGBOARD Trial Evaluating EP-104IAR for the Treatment of Knee Osteoarthritis.
Eupraxia Pharamceuticals Shares Are Trading Higher After the Company Announced It Published Its Phase 2 Data From Its SPRINGBOARD Trial Evaluating EP-104IAR for the Treatment of Knee Osteoarthritis.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.